Surface-enhanced Raman scattering (SERS) can help optimise radiotherapy treatment regimes for prostate cancer, UK scientists have shown.
Prostate cancer is the second most common cancer worldwide in men, and the fourth most common cancer overall. It is usually treated with radiotherapy, and doctors would like to tailor doses for individual patients. This would help maximise tumour cell destruction, while minimising damage to normal tissue.
To read the full article by Sarah Rogers, please visit Chemistry World.
Victoria L. Camus, Grant Stewart, William H. Nailon, Duncan B. McLarend and Colin J. Campbell